Abiraterone

Also known as: Abiraterone Acetate

Active ingredient description

Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Abiraterone
L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BX Other hormone antagonists and related agents
Discover more medicines within L02BX03

Medicines

Abiraterone is the active ingredient of these drugs:

Drug
Countries

South Africa

Poland

Hong Kong Singapore

Brazil

Poland

Brazil

Brazil

Lithuania Poland

Brazil

New Zealand United States

Brazil

South Africa

Australia Austria Brazil Canada Cyprus

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

G819A456D0 - ABIRATERONE

CAS registry number

154229-19-3 - abiraterone

SNOMED-CT

699678007 - Abiraterone (substance)